Education
About Us
Working with TipRanks
Follow Us
CellaVision AB (SE:CEVI)
:CEVI
Top Page
CellaVision AB
(OTC:CEVI)
Select Model
Select Model
Rating:72Outperform
Price Target:
kr199.00
▲(9.10% Upside)
CellaVision AB's strong financial performance, characterized by robust revenue growth and profitability, is the primary driver of its stock score. Technical indicators suggest a positive momentum, while the valuation is reasonable, offering a balanced risk-reward profile. The absence of earnings call data and corporate events does not impact the score.
CellaVision AB (CEVI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr4.49B
Dividend Yield1.35%
Average Volume (3M)15.35K
Price to Earnings (P/E)29.7
Beta (1Y)0.86
Revenue Growth3.45%
EPS Growth4.22%
CountrySE
Employees228
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.60
Shares Outstanding23,851,547
10 Day Avg. Volume13,428
30 Day Avg. Volume15,354
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CellaVision AB Business Overview & Revenue Model
Company DescriptionCellaVision AB (CEVI) is a leading provider of digital microscopy solutions for the healthcare sector, primarily focusing on clinical laboratories and medical professionals. The company specializes in innovative software and hardware products that automate the analysis of blood samples, thereby improving efficiency and accuracy in diagnostics. CellaVision's core offerings include its digital microscopy systems, which enable the remote analysis of blood smears and other biological samples, facilitating better patient care and streamlined laboratory processes.
How the Company Makes MoneyCellaVision generates revenue through the sale of its digital microscopy systems, software licenses, and related services. The company's primary revenue streams include the initial sale of its diagnostic equipment, ongoing software subscriptions, and service agreements that ensure the maintenance and support of its products. Additionally, CellaVision benefits from partnerships with key players in the healthcare and diagnostic sectors, which help to expand its market reach and enhance its product offerings. The company also engages in continuous innovation, introducing new features and updates that can lead to increased sales and customer retention.
CellaVision AB Earnings Call Summary
Earnings Call Date:Jul 18, 2025
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The call reflected a mix of strong growth in EMEA and positive strategic developments, offset by challenges in the Americas and APAC regions, and increased expenses. Despite some regional and financial fluctuations, the company's strategic initiatives and growth in core areas provide a balanced outlook.Q3-2024 Updates
Positive Updates
Strong Sales in EMEA
EMEA experienced very strong growth across multiple markets and product groups, achieving an all-time high in sales even after accounting for early orders.
Organic Growth and Improved Gross Margin
The company reported an organic growth of 9% and an increase in gross margin from 66% to 68%.
Strategic Partnership with Sysmex
Continued development of strategic partnership with Sysmex, including joint training and marketing activities.
Progress in Clinical Validation
Progress according to plan on clinical validations for the bone marrow product, with a launch expected in 2025.
Reagent Growth
Reagents showed an 11% growth, with significant performance in EMEA.
Negative Updates
Decline in Americas
Sales declined in the Americas due to political uncertainties affecting hospital order placements.
APAC Revenue Fluctuations
APAC experienced fluctuations, with no shipments to China this quarter, resulting in a revenue drop from SEK 22 million to SEK 12 million.
Increased R&D Expenses
R&D expenses rose, driven by the execution of clinical trials and the maturation of multiple programs.
Cash Flow Impacted by Working Capital
Cash flow appeared weaker than the comparable quarter, affected by working capital changes, particularly in accounts receivable and inventory.
Company Guidance
During the Q3 2024 earnings call for CEVI.ST, the executives provided guidance highlighting an organic growth of 9%, achieving a revenue of SEK 179 million compared to SEK 168 million from the previous year. The EBITDA margin was reported at 27%, equivalent to SEK 49 million. The company experienced strong sales in the EMEA region with a 50% sequential growth in instrument sales, while sales declined by 20% in the Americas due to political uncertainties affecting hospital order placements. APAC showed fluctuations, with a notable absence of shipments to China this quarter. Gross margins improved from 66% to 68%, largely driven by the implementation of price increases. Additionally, the company is progressing on strategic partnerships and clinical validation, aiming to launch a bone marrow product with a CE Mark in Europe by 2025. R&D expenses constituted 22% of sales, reflecting investments in maturing development programs, including advancements in FPM technology. The cash flow for the quarter stood at SEK 16 million, with inventory levels gradually decreasing towards normal levels.CellaVision AB Financial Statement Overview
Summary
CellaVision AB exhibits strong financial health with robust revenue growth and profitability. The balance sheet is stable with low leverage, providing resilience against economic fluctuations. Cash flow generation is healthy, although there is potential to enhance free cash flow conversion.Income Statement
CellaVision AB has demonstrated strong growth with a consistent increase in total revenue over the years, achieving a revenue growth rate of 3.41% in the TTM. The gross profit margin is robust at 68.47% for the TTM, indicating effective cost management. The net profit margin of 20.34% reflects solid profitability. Both EBIT and EBITDA margins are strong, at 26.20% and 31.53% respectively, showcasing operational efficiency.85
Very Positive
Balance Sheet
The balance sheet of CellaVision is solid with a low debt-to-equity ratio of 0.03, indicating minimal leverage. The equity ratio stands at a healthy 80.31%, showcasing financial stability. Return on equity is impressive at 18.14%, reflecting efficient use of shareholder funds. However, the low liability level might suggest underutilized leverage potential.78
Positive
Cash Flow
CellaVision's cash flow position is stable with a positive free cash flow growth rate. The operating cash flow to net income ratio is 1.24, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio at 0.44 suggests room for improvement in converting earnings into free cash flow.72
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 751.47M | 723.22M | 677.29M | 639.34M | 565.55M | 471.44M |
| Gross Profit | 517.24M | 487.07M | 463.04M | 438.32M | 392.30M | 313.04M |
| EBITDA | 230.90M | 219.75M | 207.25M | 190.87M | 193.60M | 124.60M |
| Net Income | 151.18M | 140.72M | 130.31M | 118.33M | 125.34M | 89.48M |
Balance Sheet | ||||||
| Total Assets | 1.05B | 1.01B | 928.71M | 891.75M | 825.21M | 668.02M |
| Cash, Cash Equivalents and Short-Term Investments | 155.28M | 149.43M | 121.64M | 108.05M | 130.29M | 102.26M |
| Total Debt | 30.16M | 26.85M | 64.70M | 102.50M | 136.65M | 132.78M |
| Total Liabilities | 223.83M | 196.16M | 212.32M | 250.12M | 281.93M | 238.41M |
| Stockholders Equity | 822.94M | 815.73M | 716.39M | 641.63M | 543.28M | 429.62M |
Cash Flow | ||||||
| Free Cash Flow | 78.50M | 120.69M | 109.96M | 67.85M | 75.41M | 37.47M |
| Operating Cash Flow | 206.35M | 198.44M | 196.44M | 137.28M | 159.72M | 71.12M |
| Investing Cash Flow | -86.19M | -76.01M | -85.53M | -70.01M | -84.34M | -34.96M |
| Financing Cash Flow | -86.80M | -95.09M | -97.04M | -90.41M | -48.48M | -35.22M |
CellaVision AB Technical Analysis
Positive
182.40
Price Trends
178.24
Positive
178.27
Positive
181.46
Positive
Market Momentum
2.41
Negative
53.07
Neutral
55.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CEVI, the sentiment is Positive. The current price of 182.4 is above the 20-day moving average (MA) of 182.16, above the 50-day MA of 178.24, and above the 200-day MA of 181.46, indicating a bullish trend. The MACD of 2.41 indicates Negative momentum. The RSI at 53.07 is Neutral, neither overbought nor oversold. The STOCH value of 55.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CEVI.
CellaVision AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | kr4.49B | 29.72 | 18.65% | 1.35% | 3.45% | 4.22% | |
| ― | kr6.28B | 210.07 | 1.32% | ― | 8.39% | -85.36% | |
| ― | €1.11B | 43.19 | 6.93% | ― | -5.80% | -65.99% | |
| ― | $1.66B | ― | -15.03% | ― | -21.56% | 70.41% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $932.29M | -6.14 | -35.36% | ― | 71.41% | 17.26% | |
| ― | €1.05B | -25.90 | -4.42% | ― | 13.48% | 28.98% |
* Healthcare Sector Average
SE:CEVI
CellaVision AB
183.40
-60.00
-24.65%
SE:BICO
BICO Group AB Class B
22.22
-16.32
-42.35%
SE:SEZI
Senzime AB
5.90
-0.21
-3.44%
SE:XVIVO
Xvivo Perfusion AB
187.20
-274.80
-59.48%
SE:CRAD.B
C-Rad AB Class B
33.70
3.45
11.40%
SE:SEDANA
Sedana Medical AB
10.42
-3.48
-25.04%
CellaVision AB Corporate Events
CellaVision to Present Q3 2025 Report on November 6
Oct 23, 2025
CellaVision AB announced the release of its third-quarter 2025 report on November 6, inviting analysts, investors, and media to a conference call and webcast for a presentation by CEO Simon Østergaard. This event underscores the company’s commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK199.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
CellaVision Announces Nomination Committee for 2026 AGM
Oct 21, 2025
CellaVision has announced the formation of its Nomination Committee ahead of the 2026 Annual General Meeting, scheduled for April 28 in Lund. The committee, chaired by Joel Eklund, will propose candidates for key positions such as the Chairman of the General Meeting and members of the Board of Directors. This announcement is a routine part of CellaVision’s governance process, ensuring structured leadership and strategic planning for the company’s future operations.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK199.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
CellaVision Appoints Monica Jönsson as Interim CFO
Sep 2, 2025
CellaVision has appointed Monica Jönsson as the Interim CFO, succeeding Magnus Blixt. Monica brings extensive experience from her previous roles, including her position as Group CFO at Perstorp Group. The company is in the process of recruiting a permanent CFO. This leadership change is expected to bring valuable expertise to CellaVision, potentially impacting its operations and market positioning positively.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK201.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.